Treatment of Unresectable Differentiated Thyroid Carcinoma With Upfront External Radiotherapy and Salvage Surgery: A STROBE-Compliant Retrospective Cohort Study

José F. Carrillo1, Jesús Manuel Flores2, Gilberto Espinoza3, Rafael Vázquez-Romo3, Margarita C. Ramírez-Ortega4, Liliana C. Carrillo5, Beatriz Y. Cortés-García6, Francisco J. Ochoa-Carrillo3 and Luis F. Oñate-Ocaña5*

1 Departamento de Cabeza y Cuello, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, 2 Departamento de Radioterapia, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, 3 Subdirección de Cirugía, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, 4 Dirección de Investigación, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 5 Subdirección de Investigación Clínica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, 6 Departamento de Imagen, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico

Introduction: In patients with unresectable Differentiated thyroid cancer (DTC), the use of external beam radiation therapy (EBRT), leads mostly to palliation. Our aim is to define the role of upfront EBRT, followed or not by salvage surgery, on Progression-free survival (PFS) or Overall survival (OS) in patients with DTC.

Methods: This is a cohort study of patients with initially unresectable DTC who received EBRT. Cohort A received EBRT followed by rescue surgery and cohort B, EBRT only. The Kaplan-Meier method and Cox model were employed for survival analysis.

Results: Thirty-three patients were included; 69.6% females and 30.3% males. Mean age was 60.6 and mean tumor diameter was 10.4 cm; 17 and 16 patients were included in cohorts A and B, respectively. Belonging to cohort A (Hazard ratio [HR] 0.177, 95% CI 0.05–0.7) and use of intensity modulated radiotherapy (HR 0.177, 95% CI 0.03–1.08) were associated to better PFS, while high-risk histopathology (HR 6.6, 95% CI 0.9–50) and EBRT dose (HR 1.05, 95% CI 1.01–1.08) were independently associated with lower PFS. Patients from cohort A (HR 0.061, 95% CI 0.01–0.3) had improved OS, while high-risk histopathology (HR 5.7, 95% CI 1.1–28.6) and EBRT dose (HR 1.05, 95% CI 1.01–1.09) were independently associated to worse OS.

Conclusion: EBRT, and when feasible, salvage surgery, should be an integral part of the therapeutic strategy in initially unresectable DTC.

Keywords: thyroid neoplasms, radiotherapy, thyroid surgery, locally advanced neoplasms, salvage surgery
HIGHLIGHTS

- Is unresectable differentiated thyroid cancer due to vascular invasion responsive to external beam radiotherapy, and if feasible, salvage surgery improves the oncologic outcome?
- In this cohort study, 17 patients received external beam radiation therapy followed by salvage surgery, and 16 received external beam radiation therapy only. Radiation therapy produced a high response rate which allowed successful salvage surgery, with increased disease-free and overall survival.
- Radiation therapy, and when feasible, salvage surgery should be considered in these patients; as this is a retrospective cohort study and subject to selection bias, a randomized trial is warranted.

INTRODUCTION

Thyroid cancer incidence is rising worldwide (1, 2). In Mexico, it is the second malignant neoplasm in women (3). Differentiated thyroid cancer (DTC) is mostly treated with total thyroidectomy and subsequent 131I radioiodine to ablate residual thyroid tissue or micrometastases. However, finding unresectable DTC is infrequent and not significantly addressed (2, 4).

The indications for external beam radiotherapy (EBRT) have been reported previously. The use of EBRT in patients with high-risk features for relapse and gross residual disease has been described and subject to controversy (5). Unresectable DTC patients have been treated with EBRT, mainly to obtain palliation (5, 6).

Series on unresectable DTC analyze patients who have received upfront, non-operative treatment, with EBRT, some including chemotherapy and target-aimed agents, but clinical responses or subsequent surgical resection are not described, aside from anecdotal cases (7–9). Moreover, current American Thyroid Association (ATA) guidelines do not clearly define the role of EBRT in cases with advanced unresectable DTC (10), although other guidelines suggest a palliative role of EBRT with improvement in quality of life and local disease control (11, 12).

Radioiodine resistant, locorregionally unresectable, or recurrent DTC have been treated with tyrosine kinase inhibitors like Lenvatinib. Although reports are encouraging, only 36% of patients have a partial response with high toxicity rates and increased costs (13).

Therefore, our aim is to describe the results of upfront EBRT in patients with initially unresectable DTC, and when feasible, of the addition of surgery.

MATERIALS AND METHODS

Patients

A retrospective cohort study of patients with unresectable, locally-advanced DTC admitted at our institution between January 2006 and December 2016. Inclusion criteria were patients older than 17, histopathological confirmation, normal serum thyroid function tests, no previous treatment, and the presence of unresectable neoplasms. Clinical history and physical exam, naso-pharyngolaryngoscopy, Computed tomography (CT), and Magnetic resonance angiogram of the neck and chest areas were obtained in all cases. High risk histopathology meant a poorly DTC defined by five or more mitoses per 10 high-power microscopic fields, lack of nuclear features of papillary thyroid carcinoma, and/or the presence of tumor necrosis; besides, the presence of aggressive variants of papillary thyroid carcinoma, like insular, tall cell, sclerosing, columnar, or hobnail variants were included in this category as well (14). Unresectable DTC was defined as T4a/T4b DTC and/or metastatic lymph nodes with invasion and more than 180°–without cleavage plane–surrounding of the following vascular structures: vascular structures of the root of the neck (innominate veins and artery, as well as subclavian-carotid systems), superior vena cava and/or pulmonary artery system, anterosuperior mediastinum, as well as extension to spine and neurovascular structures –including vertebral artery–, which precluded a complete excision of the mass without major risk for function or life (9).

Patients with bone and visceral metastases, except for cases with six or fewer nodular lung metastases and no evidence of pleural effusions, were excluded.

Tumor recurrence and locoregional progression were defined as the appearance of new tumor lesions or an increase in size of existing primary lesions in the neck or superior mediastinum, after R0 surgical resection or after radiotherapy completion, respectively, demonstrated by biopsy or cytology, and/or imaging findings.

Distant metastases were defined as the appearance of new lesions outside the neck and upper mediastinum, detected clinically or with imaging studies.

This study protocol is STROBE-compliant, and was accepted by “Comité de Ética en Investigación” and “Comité de Investigación” (registration number Rev/0002/2019). Written consent was not required because of the retrospective nature of the study.

External Beam Radiation Therapy

All patients received upfront EBRT. Before 2012, 3D conformal EBRT technique was used; subsequently, intensity modulated radiation therapy (IMRT).

The standard EBRT fractionation protocol and doses above 56 Gy were used if patients had an ECOG ≤ 2. Otherwise, a hypofractionation palliative course of 30–50 Gy was used. For 3D conformal technique, volume delineated in all patients was the Gross tumor volume (GTV); with doses of 56–80 Gy for patients with low ECOG. The clinical target volume (CTV) included the primary tumor and a five mm margin around the GTV: the neoplastic thyroid gland volume, tracheoesophageal grooves, central nodal compartment, and all positive nodal levels were delineated in the simulation and planning by CT.

In patients with poor ECOG, the palliative doses never exceeded 45 Gy in the GTV; the most frequently used doses were 23 and 30 Gy in 10 fractions.
IMRT and methods to integrate dose levels according to risk of recurrence were implemented according to the specialist criteria. Regions considered low risk for microscopic disease were treated with a 46 Gy dose. The “low-risk” clinical target volume (CTV) included lymph node-negative areas in the cervical neck, and the upper mediastinum to the level of the carina.

Patients were immobilized and CT images obtained every 3 mm from the skull vertex to the lungs. IMRT was planned with a gradient inverse algorithm with dose-volume constraints as previously defined (5, 6), using the Eclipse™ software and the Varian IX™ accelerator (Varian Medical Systems, Inc., Palo Alto, CA).

Response was assessed according to the RECIST criteria (15), and all measurements were performed on angio-CT scans by one CT-interpretation specialized radiologist.

Surgical Technique
Cohort A included candidates for surgical resection because of a partial RECIST response and/or with sufficient separation of the major blood vessels, which allowed surgical resection after EBRT. Cohort B included patients who refused surgery, or that were still considered unresectable after EBRT because of stable or progressive disease and consequently, surgical resection was not considered.

Surgery consisted of a total thyroidectomy with unilateral or bilateral neck dissection, in accordance with the affected lymph nodes. If needed, an anterior mediastinotomy with innominate venous and arterial system dissection was performed. Central node dissection was conducted in all cases as well. Tracheal resection was performed when indicated, as well as a postoperative tracheostomy.

Follow-Up
After treatment, patients were followed with thyroid function tests and thyroglobulin levels at three-month intervals, and CT and/or MRI every 6 months. Thyroid suppression was administered to all patients during and after EBRT administration and after surgical resection.

Statistical Analysis
Student’s t or Chi-square tests were used as required. Prognostic factors analyzed were age, gender, tumor diameter, histopathology, T, N, and M classifications, EBRT dose, protraction, dose per fraction, EBRT technique, ¹³¹I therapy, ¹³¹I dose, and clinical response according to RECIST criteria. Survival data were analyzed with the Kaplan-Meier and Logrank methods and the Cox’s model. PFS was calculated from EBRT initiation to recurrence/progression event; OS was calculated from diagnosis until the last visit or death. Prognostic factors associated with PFS or OS with a probability value of 0.2 or less, by bivariate analysis, were included in the multivariate analyses. Hazard ratios (HR) were obtained as a measurement of association with 95% confidence intervals (95% CI). The final model was selected according to accomplishment criteria and goodness-of-fit tests; the final model was examined for proportionality assumptions and interaction terms.

Neither final exposure variables nor outcome data presented missing values. Missing data analysis showed that missingness were at random; multivariate regression imputation was employed as required. Probabilities of 0.05 or less were considered significant, two-tailed statistics were used, and SPSS statistical software for Mac, version 23 (IBM Corp., Armonk, NY, USA) were employed.

RESULTS
Patients
Of 1,438 patients with DTC, 33 (2.29%) met the inclusion criteria; 23 (69.6%) were females and 10 were males (30.3%). Mean age was 60.6 years (Standard deviation [SD] 14.6). Mean tumor diameter was 10.35 cm (SD 4.2). Complete resection after EBRT was achieved in 17 cases (cohort A); 16 cases were allocated in cohort B. Fewer patients in cohort B received ¹³¹I radioiodine treatment, fewer received EBRT by IMRT technique and fewer had response by RECIST than patients in cohort A (Table 1).

EBRT
Eight (47.1%) and two (12.5%) patients in cohorts A and B received IMRT respectively, while nine (52.9%) and 14 (87.5%) cases had conformational therapy, respectively. Patients in cohort A received a mean dose of 51.4 Gy (SD 20.6) and those in cohort B 53.9 Gy (SD 18.9). Other treatment characteristics with radiation therapy by cohorts are listed in demographic and descriptive Tables 1 and 2. All patients in cohort A had partial responses (PR) or a response which permitted surgery. In cohort B three cases had progressive or stable disease (18.8%), other three patients (18.8%) a partial response, and the rest a minor response insufficient to qualify for PR according to RECIST criteria. No case in our series reached a complete response.

Radiation therapy-associated morbidity included grade III radio-epithelitis and xerostomia in seven (21%) and eight cases (24.4%), respectively. Dysphagia due to mucositis occurred in 12 (36%) cases and required percutaneous endoscopic gastrostomy (PEG). In four cases (12.12%) in which tracheal invasion was present, upper airway obstruction led to performance of a tracheostomy. One of these patients has not been decannulated after 4 years of follow-up, while the rest are now deceased.

Initially, there were three (9.09%) cases with lung metastases. Metastases developed during follow-up in nine cases (27.27%), and included five lung (15.5%), two bone (6.06%) and two brain metastases (6.06%).

Surgery
The median interval time between EBRT and surgery was 13.27 months (2.3–81). Total thyroidectomy and unilateral neck dissection were performed in 14 cases, with bilateral neck dissection in three. Additional mediastinotomy was performed in three cases, and tracheal resection in two. One patient who had surgery had an R2 resection, and was subjected to a second surgical procedure which included mediastinotomy and reached an R0 status. The rest of the cohort A patients had an R0 status after
### TABLE 1 | Demographic and clinical characteristics of patients by cohort (N=33).

| Factor | Cohort A (N=17) | Cohort B (N=16) | P  |
|--------|----------------|----------------|----|
| Gender* | Female | 12 (70.5) | 11 (68.7) | 0.603 |
|         | Male   | 5 (31.2)  | 5 (29.4)  |     |
| Age (years) | 54.9 (13.1) | 66.6 (14)  | 0.019 |
| Tumor diameter (cm) | 8.70 (3.8) | 12 (4.6)  | 0.031 |
| Histopathology* | classic | 15 (88.2) | 14 (87.5) | 0.948 |
|         | high-risk | 2 (11.8) | 2 (12.5) | 0.909 |
| T classification* | T4a | 2 (11.7) | 2 (12.5) | 0.909 |
|         | T4b | 15 (88.2) | 14 (87.5) |     |
| N classification* | N1b | 17 (100) | 16 (100) | 0.948 |
| M classification* | M0 | 14 (82.4) | 10 (62.5) | 0.198 |
|         | M1 | 3 (17.6) | 6 (37.5) |     |
| EBRT dose (Gy) | 51.4 (20.6) | 53.9 (18.9) | 0.708 |
| Protraction (weeks) | 12.01 (16.5) | 11.3 (14.8) | 0.894 |
| Dose per fraction (Gy) | 3.12 (1.96) | 2.95 (1.61) | 0.777 |
| EBRT technique* | ARC | 9 (52.9) | 14 (87.5) | 0.027 |
|         | IMRT | 8 (47.1) | 2 (12.5) |     |
| ¹³¹I therapy* (received) | 16 (41.1) | 3 (18.8) | <0.0001 |
| ¹³¹I Dose (mCi) | 223.3 (75.3) | 183.3 (28.9) | 0.387 |
| Clinical Response* (RECIST) | Progressive or stable disease | 0 | 3 (18.8) | 0.061 |
|         | Partial response | 17 (100) | 13 (81.3) |     |

N, number of patients; *categorical variables and numbers are absolute counts (percentages); others are continuous variables and numbers represent means (standard deviation); EBRT, external beam radiotherapy; ARC, conformational; IMRT, intensity modulated; Gy, Grays; mCi, milliCuries; P, probability values.

### TABLE 2 | Description of cases of differentiated thyroid carcinoma treated with upfront radiotherapy and surgery.

| No. | Age | G | TD | T | N | M | EBRT Technique | Dose (Gy) | Sx | R | ECOG | P | RAI Dose | Status |
|-----|-----|---|----|---|---|---|----------------|-----------|----|---|------|----|-----------|--------|
| 1   | 83  | M | 8  | T4b | N1b | 0 | Conformal | 69 | Yes | R0 | 1 | WD | 300 | DWD |
| 2   | 53  | F | 8  | T4b | N1b | 0 | Conformal | 65 | Yes | R0 | 1 | WD | 300 | DWD |
| 3   | 67  | F | 8  | T4a | N1b | 0 | Conformal | 65 | No  | 1  | 0  | DWD |
| 4   | 68  | F | 10 | T4b | N1b | 0 | Conformal | 70 | No  | 1  | tall cells | 0 | DWD |
| 5   | 67  | F | 12 | T4a | N1b | 0 | Conformal | 65 | No  | 1  | PD  | 0 | DWD |
| 6   | 75  | M | 8  | T4a | N1b | 1 | Conformal | 45 | No  | 2  | WD | 150 | DWD |
| 7   | 74  | F | 10 | T4b | N1b | 1 | Conformal | 70 | No  | 1  | WD | 0 | DWD |
| 8   | 55  | F | 10 | T4b | N1b | 0 | Conformal | 30 | No  | 3  | WD | 0 | DWD |
| 9   | 64  | F | 7  | T4a | N1b | 1 | Conformal | 66 | Yes | R0 | 1 | WD | 350 | DWD |
| 10  | 54  | M | 5  | T4a | N1b | 0 | Conformal | 30 | Yes | R0 | 3 | WD | 150 | AWOD |
| 11  | 30  | F | 8  | T4b | N1b | 0 | Conformal | 40 | Yes | R0 | 1 | WD | 150 | AWOD |
| 12  | 54  | F | 6  | T4b | N1b | 0 | IMRT | 45 | Yes | R0 | 1 | PD | 200 | AWOD |
| 13  | 60  | M | 12 | T4b | N1b | 1 | IMRT | 66 | Yes | R0 | 1 | WD | 200 | AWOD |
| 14  | 43  | F | 8  | T4b | N1b | 0 | Conformal | 23 | Yes | R0 | 3 | WD | 200 | AWOD |
| 15  | 47  | F | 8  | T4b | N1b | 1 | Conformal | 23 | Yes | R0 | 3 | WD | 200 | AWOD |
| 16  | 61  | F | 5  | T4b | N1b | 0 | Conformal | 43 | Yes | R0 | 2 | WD | 200 | AWOD |
| 17  | 50  | F | 20 | T4b | N1b | 0 | IMRT | 60.2 | Yes | R2-0 | 1 | WD | 200 | AWOD |
| 18  | 78  | F | 8  | T4b | N1b | 0 | Conformal | 70.2 | No  | 1  | WD | 200 | DWD |
| 19  | 82  | F | 8  | T4b | N1b | 0 | IMRT | 60.2 | Yes | R0 | 1 | WD | 150 | DWD |
| 20  | 34  | F | 15 | T4b | N1b | 0 | IMRT | 70  | No  | 1  | WD | 0 | AWD |
| 21  | 46  | F | 7  | T4b | N1b | 0 | IMRT | 68  | Yes | R0 | 1 | WD | 150 | AWOD |
| 22  | 43  | F | 18 | T4b | N1b | 1 | Conformal | 47  | No  | 1  | WD | 0 | DWD |
| 23  | 75  | F | 18 | T4b | N1b | 0 | Conformal | 45  | No  | 2  | WD | 0 | DWD |
| 24  | 48  | F | 7  | T4b | N1b | 0 | Conformal | 43  | Yes | R0 | 2 | WD | 250 | AWOD |
| 25  | 77  | M | 15 | T4b | N1b | 0 | Conformal | 30  | No  | 3  | WD | 0 | AWD |
| 26  | 38  | M | 20 | T4b | N1b | 0 | Conformal | 23  | No  | 3  | WD | 0 | AWD |
| 27  | 48  | M | 8  | T4b | N1b | 0 | IMRT | 46  | Yes | R0 | 2 | Insular | 0 | DWD |
| 28  | 67  | M | 18 | T4b | N1b | 1 | Conformal | 23  | No  | 3  | WD | 0 | AWD |
| 29  | 58  | F | 8  | T4b | N1b | 1 | Conformal | 74  | No  | 1  | WD | 0 | DWD |
| 30  | 50  | F | 15 | T4b | N1b | 0 | Conformal | 66  | Yes | R2 | 1  | WD | 250 | AWOD |
| 31  | 71  | F | 6  | T4b | N1b | 1 | IMRT | 66.6 | No  | 2  | WD | 200 | DWD |
| 32  | 79  | M | 8  | T4b | N1b | 0 | Conformal | 70  | No  | 2  | WD | 0 | DWD |
| 33  | 61  | M | 8  | T4b | N1b | 0 | IMRT | 60  | Yes | R0 | 1 | WD | 100 | AWOD |

No., number; G, Gender; TD, Tumor Diameter; EBRT, External Beam Radiotherapy; IMRT, Intensity Modulated Radiotherapy; Gy, Grays; Sx, Surgery; R, Resection type; P, Pathology; WD, Well differentiated; RAI, Radioactive Iodine; AWOD, Alive Without Disease; AWD, Alive with disease; DWD, Dead With Disease; DWOD, Dead without Disease.
surgery. Postoperative morbidity included temporal and permanent laryngeal nerve injury in five (29.4%) and five cases (29.4%), respectively. Transient and permanent hypoparathyroidism occurred in one (5.8%) and two (11.6%) cases, respectively. There was major surgical bleeding (≥500 ml) in five (29.4%) cases, pneumothorax in four (23.5%), and a chylous fistula in four (23.5%).

There were two cases each with high-risk histopathology in Cohorts A and B.

Three patients (9.09%) had no surgery based on a personal decision, although they were candidates for surgical resection and were included in cohort B. One of them had progression at 14 months follow-up, and the other two are alive and with no signs of locoregional progression or metastases.

There was one case of surgery-related death due to laceration of the innominate artery which was repaired by carotid artery-proximal innominate artery Gore-Tex grafting and right subclavian artery ligation. Patient developed a major stroke during the following 12-h period and pronounced dead and was included as an event in the survival analysis.

From cohort A, three patients had locoregional recurrences which were treated with neck dissection. Patients developed progressive lung metastases and died in spite of treatment with 131I radioiodine and TSH suppression. Another case had progression of already present lung metastases which were treated with 131I radioiodine, TSH suppression, and sorafenib without response. Finally, a fifth patient had lung metastases progression treated with 131I radioiodine, TSH suppression and is alive and stable with lung disease.

Survival
Median follow-up was 2.74 years (0.5–7.9). Median PFS in all patients was 3.72 years (95% CI 2.2–5.2). There were 17 recurrence/progression events in both cohorts (51.5%); five were in cohort A (29.4%) and 12 in cohort B (75%) (p = 0.009). Median PFS in cohorts A and B were 6.03 (95% CI 3.37–8.7) and 0.89 years (95% CI 0–3.82), respectively.

Age, presence of distant metastases, 131I radioiodine therapy administration, EBRT dose, and patients who underwent surgery (cohort A) were significantly associated with PFS by bivariate analysis (Table 3). High-risk histopathology, Conformational EBRT technique, EBRT total dose, and absence of surgery (cohort B) were independent explanatory factors associated with lower PFS by multivariate analysis (Table 4).

Median OS of all patients was 5.07 years (95% CI 3.1–6.9). There were 17 events of death in both cohorts (51.5%); five in cohort A (29.4%), and 12 in cohort B (75%) (Logrank p = 0.009). Median OS in cohorts A and B was 6.9 (95% CI 5.5–8.2) and 1.6 (95% CI 0–4.7) years, respectively.

Age, 131I radioiodine therapy administration, EBRT dose, clinical response by RECIST and inclusion in cohort A were associated with OS by bivariate analysis (Table 3). High-risk histopathology, EBRT dose, and belonging to cohort B were independent explanatory factors associated with worse OS by multivariate analysis (Table 4).

The proportionality assumptions were satisfactory in both models. The presence of interaction terms was investigated in both final models and none were found. Figure 1 depicts the PFS and OS survival curves by cohort (constructed using the final Cox models described in Table 4).

Representative Case
Figure 2 shows the case of a 38-year-old female, diagnosed with DTC who received IMRT radiotherapy in 2014, with more than 30% response. She underwent a total thyroidectomy and left

| TABLE 3 | Bivariate association of various factors and progression-free or overall survival (N = 33). |
| Factor | Gender* | HR (95% CI) PFS | P (PFS) | HR (95% CI) OS | P(OS) |
| Gender* | Female | 1 | 0.449 | 1 | 0.487 |
| Gender* | Male | 0.214 (0.13–0.159) | 0.669 (0.22–2.076) | 0.036 |
| Age | (years) | 1.038 (1.003–1.07) | 1.039 (1.002–1.08) | 0.829 |
| Age | | 0.309 (0.1–0.52) | 0.102 (0.06–0.18) | 0.003 |
| Tumor diameter | (cm) | 1.013 (0.89–1.14) | 1.013 (0.9–1.14) | 0.586 |
| Histopathology* | classic | 0.968 (0.2–4.59) | 1.446 (0.383–5.45) | 0.74 |
| Histopathology* | high-risk | 1 | 0.446 | 0.802 (0.22–2.95) | 1 |
| M classification* | T4a | 1 | 0.011 | 0.081 (0.02–0.28) | 0.167 |
| M classification* | M0 | 1 | 0.034 | 0.022 (0.02–0.21) | 0.029 |
| EBRT dose | (Gy) | 1.033 (1.002–1.06) | 1.037 (1.004–1.07) | 0.901 |
| Protraction | (weeks) | 0.998 (0.97–1.03) | 0.998 (0.968–1.03) | 0.075 |
| EBRT technique* | ARC | 0.746 (0.49–1.12) | 0.587 (0.33–1.054) | 0.218 |
| 131I therapy* | IMRT | 0.274 (0.06–1.21) | 0.454 (0.13–1.594) | 0.008 |
| 131I Dose | (mCi) | 1 | 0.029 | 1 | 0.987 |
| Clinical Response* | RECIST | 1 | 0.029 | 1 | 0.0002 |
| Clinical Response* | progression or stable disease | 1 | 1 | 1 | 0.0002 |
| Partial response | 1 | 0.009 (0.02–0.2) | 1 | 0.003 |
| Cohort | B | 1 | 0.003 | 0.102 (0.02–0.46) | 0.003 |

N, number of patients; *categorical variables; HR, Hazard ratios; CI, confidence intervals; PFS, progression-free survival; OS, overall survival; T: tumor classification, M: metastases classification; EBRT, external beam radiotherapy; ARC, conformational; IMRT, intensity modulated; Gy, Grays; mCi, miliCuries; P, probability value.
modified radical neck dissection in 2016, and is currently disease-free.

**DISCUSSION**

Patients with locally advanced DTC are treated with surgery, which sometimes includes extensive procedures; some researchers considering radiation therapy as complementary, and in R0 cases, as adjuvant treatment (5, 6).

When the extent of malignancy is associated with invasion to vascular structures of the base of the neck and upper mediastinum precluding a safe and clear resection, the therapeutic options are limited to observation, symptomatic treatment, and/or palliative EBRT.

Some isolated case-series exist where DTC cases considered unresectable receive chemotherapy, targeted agent therapy or EBRT and then subjected to a surgical procedure, occasionally attaining complete resection (7, 8). The objective of these anecdotal reports is to underscore palliation, with an R0 resection obtained in one or two cases.

A 20% and 50% three-year locoregional control has been obtained in patients treated with palliative or radical radiotherapy, respectively, in unresectable DTC, with no further attempt to perform surgery after EBRT. Frequently, cases in these analyses had undergone incomplete surgical resections (16–18).

Current guidelines consider EBRT administration indicated in cases where surgery has been performed but with gross residual disease, and even in these circumstances, radiotherapy use is controversial (10, 12).

Partial resection and complementary radiotherapy are less efficient because of the presence of scarred, neoplastic and non-oxygenated tissue after treatment. Further, the possibilities of obtaining a cure are nil.

Our patients were considered unresectable due to major invasion of the vascular structures of the base of the neck and upper mediastinum, including the innominate vein and artery systems, as well as the subclavian-carotid and aortic arch structures. Main findings of our study are that EBRT has an efficient role in management of unresectable DTC and that IMRT plus salvage

---

**TABLE 4** | Multivariate association of various factors and progression-free survival or overall survival (N=33).

| Factors (outcome PFS) | β     | S.E.  | expβ (HR) | (95% CI)       | P     |
|-----------------------|-------|-------|-----------|----------------|-------|
| High-risk histopathology | 1.9   | 1.031 | 6.888     | 0.89–50.5       | 0.065 |
| EBRT technique (IMRT) | −1.731| 0.926 | 0.177     | 0.029–1.08      | 0.062 |
| EBRT dose (Gy)        | 0.045 | 0.016 | 1.046     | 1.01–1.08       | 0.005 |
| Cohort B              | −1.731| 0.7    | 0.177     | 0.045–0.69      | 0.013 |

| Factors (outcome OS)  | β     | S.E.  | expβ (HR) | (95% CI)       | P     |
|-----------------------|-------|-------|-----------|----------------|-------|
| High-risk histopathology | 1.738 | 0.825 | 5.886     | 1.129–28.6      | 0.035 |
| EBRT dose (Gy)        | 0.051 | 0.019 | 1.053     | 1.014–1.093     | 0.007 |
| Cohort B              | −2.803| 0.843 | 0.061     | 0.01–0.317      | 0.001 |

N, number of patients; β, regression coefficient; S.E., standard error of the regression coefficient; expβ, beta exponent or HR, Hazard ratios; CI, confidence intervals; P, probability value; PFS, progression-free survival; OS, overall survival; EBRT, external beam radiotherapy; Gy Grays (PFS model -2 Log Likelihood = 64.1; p=0.000082; OS model -2 Log Likelihood 66.6; p = 0.000017).
surgery were associated with an increased PFS/OS, while high-risk histopathology decreased PFS (Table 3).

In this study, the median PFS in patients who underwent salvage surgery was six years, and was superior to the findings of Terezakis (5), who described that patients left with gross residual disease had locoregional control (LRC) of 62% at 4 years, with no attempt to perform surgery after EBRT. The improvement in PFS associated with the use of IMRT has been suggested in previous reports (19), where no surgery was attempted. Although the number of cases treated with IMRT was small (ten cases), partial response occurred in eight (80%) which allowed an R0 resection, while surgical resection with conformal radiotherapy was achieved in 39% of cases.

Higher doses of EBRT were associated to decreased DFS and OS by multivariate analyses, probably because of selection bias resulting from need to treat larger tumors more aggressively.

As expected, the presence of aggressive histopathology was confirmed to be a factor associated with an increased risk of recurrence, progression and death.

In this cohort study, with a median follow-up of 2.74 years, successful rescue surgery was independently associated with improved PFS and OS. This finding underscores the significance of a complete resection when feasible, since these patients usually receive a palliative treatment.

A word of caution should be given, since our objective was not a comparison between EBRT treated cases and those who received Surgery plus EBRT, but to underline a positive effect of EBRT on unresectable DTC, with better oncologic outcomes when surgery becomes feasible.

This is the first report, to our knowledge, in which a comprehensive evaluation and a salvage surgical resection are attempted in initially unresectable DTC in patients who previously received an upfront EBRT course.

The time interval before surgical intervention was performed in operable cases was a median of 13.3 months, which underscores the long-term effect of radiotherapy on DTC, which has not been previously described. Aside, the potential deleterious effect of fibrosis caused by EBRT—with the increased risks for a surgical procedure— is diminished after this time period has elapsed.

We devised a different strategy of not performing debulking surgery, as previously reported, but to administer a radical dose of EBRT. Subsequently, surgical feasibility was evaluated with the potential advantage of preventing tumor dissemination and scarring after an R2 procedure which in turn, could preclude surgical rescue after radiotherapy administration (20).

Metastases were infrequent in these cohorts, of not major significance on PFS or OS, specifically in the multivariate analyses; this suggests that our strategy has potential impact in the control of this factor since it allows the administration of $^{131}$I radiiodine with improvement in the oncologic outcome.

EBRT toxicity was significant; the most frequent complications were upper airway and esophageal obstruction, which were managed with temporary tracheostomy and PEG. In spite of the extensive radiation fields, no major or death-related toxicity was reported in our series. Although there was a trend toward a greater incidence of toxicity with conformal therapy, this had no significance; lower toxicity rates are obtained with the
administration of IMRT (21), and secondarily, a greater target-directed dose delivery.

In our cohorts, aside from greater frequencies of hypoparathyroidism and laryngeal nerve palsy, either transitory or permanent, than those reported, there was a significant percentage of cases with major bleeding and pneumothorax, and one patient died during the procedure due to laceration of the innominate artery. In spite of this relatively high rate of surgical complications, these are expected to occur due to the extent of dissection and the presence of scarring and edema in previously radiated tissues (20).

Same consideration could be applied to the one death reported (where even with a partial response and complete dissection of the lesion) infiltration of the great vessels persisted and led to uncontrollable bleeding. Even after a major response to EBRT, we believe that if the lesion is still encircling the great vessels by more than 180°, and there is dubious invasion or contact with pulmonary vessels, surgery should not be attempted, although there are case reports of venous and arterial grafting, albeit with a high operative death rate (20), early recurrence and the development of metastases.

In spite of this drawback, radiotherapy in our patients – especially after the administration of IMRT– contributed to the creation of a lower tumor volume and more defined dissection planes, thus allowing a safer and realistic surgical plan to conduct an R0 resection in initially non-resectable cases.

The retrospective nature of our data and relatively small number of cases, are the main drawbacks of this study. However, and given the paucity of unresectable DTC cases who are candidates for upfront EBRT and eventual rescue surgery, this cohort study constitutes, to our knowledge, one of the largest available.

Other limitations include the change over time from conformational 3D therapy to IMRT, and the lack of a health-related quality of life evaluation. Although the change in EBRT technique increased the heterogeneity of our analyses, it also allowed us to conduct an internal comparison of the efficiency of both methods, resulting in a clear advantage of IMRT in terms of PFS. HRQL was not formally evaluated in this cohort, but the decreased complication rate associated to IMRT and the oncologic outcomes obtained after resection suggest that, in future multicenter studies, the application of the strategy described will lead to better PFS and OS results, and consequently HRQL.

Ideally, a randomized controlled trial would be the instrument required to settle the controversy on the role of EBRT and potential salvage surgery in patients with initially unresectable DTC. However, previous attempts to perform an adequate randomized controlled trial, have been closed early due to the small numbers of recruited patients (21).

CONCLUSION

A favorable LRC rate and OS after EBRT in unresectable DTC cases secondary to major invasion of the mediastinum and lower neck vascular structures is demonstrated. Moreover, EBRT results improved significantly with the addition of surgery.

EBRT [especially IMRT (20, 22)] and when feasible, salvage surgery, should be an integral part of the management of unresectable DTC.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comité de Investigación and Comité de Ética en Investigación. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

Study concepts: JC, JF, FO-C, and LO-O. Study design: JC, RV-R, and LO-O. Data acquisition: JF, GE, RV-R, LC, and BC-G. Quality control of data and algorithms: JC, GE, BC-G, FO-C, and LO-O. Data analysis and interpretation: JC, MR-O, LC, FO-C, and LO-O. Manuscript preparation: JC, RV-R, BC-G, FO-C, and LO-O. Manuscript editing: JC, JF, GE, MR-O, LC, FO-C, and LO-O. Manuscript review: All authors. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

The authors thank Professor Deborah Alemán-Hoey, MD, for her kind support with the English language editorial review.

REFERENCES

1. Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. *Endocrinol Metab Clin North Am* (2019) 48:23–35. doi: 10.1016/j.mec.2018.10.002
2. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. *Lancet* (2016) 388:2783–95. doi: 10.1016/S0140-6736(16)30172-6
3. Ferlay J, Ervik M, Lam F, et al. *Global Cancer Observatory: Cancer Today* (2018), Lyon, France: International Agency for Research on Cancer. Available at: https://gco.iarc.fr/today (Accessed June 9, 2020).
4. Carling T, Udelsman R. Thyroid cancer. *Annu Rev Med* (2014) 65:125–37. doi: 10.1146/annurev-med-061512-105739
5. Teresakis SA, Lee KS, Ghussein RA, Rivera M, Turtle RM, Wolden SL, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center
experience. Int J Radiat Oncol Biol Phys (2009) 73:795–801. doi: 10.1016/j.ijrobp.2008.05.012
6. Kiess AP, Agrawal N, Brierley JD, Duvvuri U, Ferris RL, Genden E, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. Head Neck (2016) 38:493–8. doi: 10.1002/hed.24357
7. Besic N, Auersperg M, Dremelj M, Vidergar-Kralj B, Gazic B. Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma. Thyroid (2013) 23:178–84. doi: 10.1089/thy.2012.0194
8. Besic N, Dremelj M, Pilko G. Locoregional disease control after external beam radiotherapy in 91 patients with differentiated thyroid carcinoma and pT4 tumor stage - a single institution experience. Radiol Oncol (2018) 52:453–60. doi: 10.2478/radio-2018-0038
9. Shindo ML, Caruana SM, Kandil E, McCaffrey JC, Orloff LA, Porterfield JR, et al. Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement. Head Neck (2014) 36:1379–90. doi: 10.1002/hed.23619
10. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2016) 26:1–133. doi: 10.1089/thy.2016.0028
11. Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol (2016) 130:S150–60. doi: 10.1017/S0022215116000578
12. Haddad RI, Nasr C, Bischoff L, Carrillo et al. Upfront Radiotherapy in Thyroid Cancer
13. Locati LD, Piovesan A, Caruana SM, Kandil E, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45:228–47. doi: 10.1016/j.ejca.2008.10.026
14. Ibrahimpasic T, Ghossein R, Shah JP, Ganly I. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid (2019) 29:311–21. doi: 10.1089/thy.2018.0509
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. Indications of external beam radiation therapy in non-anaplastic thyroid cancer and impact of innovative radiation techniques. Crit Rev Oncol Hematol (2013) 86:52–68. doi: 10.1016/j.critrevonc.2012.09.007
16. Kim TH, Chung KW, Lee YJ, et al. The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer. Radiat Oncol (2010) 5:69. doi: 10.1186/1748-717X-5-69
17. Ishigaki T, Uruno T, Tanaka T, Ogimi Y, Masaki C, Akaishi J, et al. Usefulness of stereotactic radiotherapy using the CyberKnife for patients with inoperable locoregional recurrences of differentiated thyroid Cancer. World J Surg (2019) 43:513–8. doi: 10.1007/s00268-018-4813-5
18. So K, Smith RE, Davis SR. Radiotherapy in well-differentiated thyroid cancer: is it underutilized? ANZ J Surg (2016) 86:696–700. doi: 10.1111/ans.13374
19. Beckham TH, Romesser PB, Groen AH, Sabol C, Shah A, Sabra M, et al. Intensity-Modulated Radiation Therapy with or without concurrent chemotherapy in nonanaplastic thyroid cancer with unresectable or gross residual disease. Thyroid (2018) 28:1180–9. doi: 10.1089/thy.2018.0214
20. Wada N, Masudo K, Hirakawa S, et al. Superior vena cava (SVC) reconstruction using autologous tissue in two cases of differentiated thyroid carcinoma presenting with SVC syndrome. World J Surg Oncol (2009) 7:75. doi: 10.1186/1477-7819-7-75
21. Biermann M, Pixberg M, Riemann B, et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin (2009) 48:89–90. doi: 10.3413/nukmed-0221
22. Sun XS, Sun SR, Guévara N, Marcy PY, Peyrottes I, Lassalle S, et al. Indications of external beam radiotherapy in non-anaplastic thyroid cancer and impact of innovative radiation techniques. Crit Rev Oncol Hematol (2013) 86:52–68. doi: 10.1016/j.critrevonc.2012.09.007

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.